Navigation Links
VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes
Date:6/8/2009

ted group was the result of more aggressive medication intervention, while concurrent anti-diabetic medications were reduced in patients treated with Qnexa to meet the same glycemic thresholds. The results of the DM-230 study had previously been released but the ADA podium presentation represents the first time the trial results have been shared with the scientific and medical community.

Qnexa was well-tolerated, with no drug-related serious adverse events. The most common drug-related adverse events reported over the 56 weeks for the treatment and placebo groups, respectively, were tingling, nausea, dry mouth, dizziness, insomnia and constipation. Patients were monitored for depression and suicidality using the PHQ-9 questionnaire, the FDA's preferred mental health assessment tool. Patients treated with Qnexa demonstrated greater improvements in PHQ-9 scores from baseline to the end of the study than the placebo group, providing further assurance that Qnexa treatment does not produce significant adverse mood changes or suicidality.

Despite a mean baseline HbA1c level of 8.7 percent, 53 percent of the subjects treated with Qnexa were able to achieve the ADA recommended goal of 7.0 percent or lower, versus 40 percent of the subjects in the placebo arm (p<0.05). The incidence of treatment-related hypoglycemia was similar in the treatment and placebo arms (2.7% and 1.8%, respectively). There were no cases of severe hypoglycemia.

About Diabetes

Diabetes, a chronic medical condition, affects more than 23 million people in the United States and nearly 250 million people worldwide. An estimated 17.9 million have been diagnosed with the disease, however, nearly one quarter are unaware that they have diabetes. New cases of diabetes doubled over the last ten years due to obesity and lifestyle and it is now calculated that the lifetime risk of diabetes in this century is approximately 35 per
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. New Diabetes Drug Shows Promise in Trial
2. Vaporized viral vector shows promise in anti-cancer gene therapy
3. New Survey Shows Americans Strongly Support Guaranteed Dental Coverage in Healthcare Reform
4. Global Testing Shows No Variation in Swine Flu Virus
5. New Study Shows Many U.S. Contact Lens Wearers Do Not Comply With Recommended Replacement Schedules
6. Protein may be strongest indicator of rare lung disease, study shows
7. People who wear rose-colored glasses see more, University of Toronto study shows
8. Computer modeling shows strategies to rein in epidemics need to be retooled for rural populations
9. New study shows people with mental health problems receive inadequate medical care
10. The Killing of George Tiller: Video "Thine Eyes" Shows True Face of Pro-life Movement in the Face of 'Terrorist' Accusations
11. New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... Hamilton, ON. Dec. 6, 2009 A new study ... disorder known as venous thromboembolism (VTE). , The ... Americans every year, and occurs when an abnormal clot ... blood, causing pain and swelling. In some cases, the ... travel through the heart to the lungs, causing a ...
(Date:12/6/2009)... organizations and members of the community, in cooperation with the Greater ... a holiday party. This year,s attendance is expected to soar to ... , ... (PRWEB) December 6, 2009 -- Volunteer ... VA Healthcare System in West Los Angeles, will once again create ...
(Date:12/5/2009)... three-drug combination has shown in a phase 1/2 ... in the treatment of patients newly diagnosed with multiple ... marrow, say researchers from Dana-Farber Cancer Institute. , Partial ... 66 patients treated with the drug combination in the ... partial response rate" in the phase 2 population, reports ...
(Date:12/5/2009)... WASHINGTON, Dec. 5 ,, What: Cuts ... a difference in the fight against cancer and other terminal ... will be donated to St. Jude Children,s Research Hospital. Guests ... Sisters, a delectable and savory Vietnamese restaurant in Falls Church ...
(Date:12/5/2009)... Cancer Is Most Challenging-- ,, PHILADELPHIA and ... specific genes, dubbed partner genes, that fuse with another ... infants. By more accurately defining specific partner genes, researchers ... particular treatments. ,, Oncologists also aim to use ...
Breaking Medicine News(10 mins):Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life &#8220;Heroes&#8221; 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life &#8220;Heroes&#8221; 3Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4
... to 2.2 million additional cases in U.S. by 2050 , , ... dehydration linked to global warming will boost kidney stone rates ... suggests. , In the United States in particular, hotter weather ... among residents of southern states -- the so-called "kidney-stone belt." ...
... food diary program to aid in weight loss efforts is offered ... ... July 14 Recognizing the,importance of educating consumers about the nutritional ... site at, http://www.sunkistdailydiet.com to provide users with a free, easy-to-use,always ...
... Ancillary Group ... Benefits -, PHILADELPHIA, ... LNC ) today announced it,will move to a new and expanded Dental ... October 1, 2008. The,Lincoln DentalConnect(SM) plan, provides access to more than 52,000 ...
... and 50 local students, WHAT: To help celebrate the kick off of the ... will conduct a fitness clinic to encourage ... drinking milk, Four lucky students ... Josh Boone,s week long basketball camp., WHY: With the ...
... to the brain, heparin more risky, study finds , , MONDAY, ... heparin is associated with an increased risk of serious bleeding ... shows. , But another thinning agent, warfarin, did not ... of patients. , This finding led the authors of a ...
... Study found those who were more fit had larger ... and women with early-stage Alzheimer,s disease who were more ... counterparts in less stellar shape. , The findings, though ... the brain atrophy (shrinkage) associated with Alzheimer,s disease. Or ...
Other Medicine News:Health News:Global Warming Linked to Heightened Kidney Stone Risk 2Health News:Global Warming Linked to Heightened Kidney Stone Risk 3Health News:Use of Food Diary Helps Increase Weightloss 2Health News:Lincoln Financial Group Announces New Dental Panel of Providers 2Health News:Lincoln Financial Group Announces New Dental Panel of Providers 3Health News:Warfarin Safer Than Heparin for Some Strokes 2Health News:Exercise Might Slow Brain Shrinkage in Alzheimer's Patients 2Health News:Exercise Might Slow Brain Shrinkage in Alzheimer's Patients 3
(Date:12/4/2009)... Inc. (NYSE Amex: PIP ), a biodefense company ... today the presentation of new data from the Company,s ... Antigen (rPA) based anthrax vaccine is structurally stable and ... and including 55 degrees C. The data were ...
(Date:12/4/2009)... 4 Hospira, Inc. (NYSE: HSP ), ... today announced the launch of its next-generation 50 mL ... and solutions, and now offers a complete size range ... responsible VisIV product. The launch of the 50 mL ...
(Date:12/4/2009)... PharmAthene, Inc. (NYSE Amex: PIP ), ... and chemical threats, announced today that the Company ... effectiveness of Valortim® in an inhalation anthrax model ... The data are being presented during an oral ...
Breaking Medicine Technology:PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 2PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 3PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 4PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop 5Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 2Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 3Hospira Expands VisIV(TM) Portfolio to Offer Complete Range of Environmentally Friendly I.V. Containers 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6AMICAS PACS For Mammography at RSNA 2009 61273 1AMICAS PACS For Mammography at RSNA 2009 61273 2AMICAS PACS For Mammography at RSNA 2009 61273 3Reportlinker Adds Diclofenac sodium 28CAS 15307 79 6 29 Market Research Report 2009 14821 1Reportlinker Adds Diclofenac sodium 28CAS 15307 79 6 29 Market Research Report 2009 14821 2Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 1Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 2Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 3Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 4Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 5Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 6Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 7Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 8Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 9Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 10Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 11Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 12Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 13Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 14Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 15Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 16Reportlinker Adds US Orthopedic Devices Market Analysis 26amp 3B Forecasts to 2015 6234 17
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: